Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis

苯拉唑马布 医学 哮喘 恶化 安慰剂 内科学 人口 嗜酸性粒细胞 美波利祖马布 环境卫生 病理 替代医学
作者
Giorgio Walter Canonica,Tim Harrison,Pascal Chanez,Francesco Menzella,Renaud Louis,Borja G. Cosío,Njira Lugogo,Arjun Mohan,Annie Burden,Esther García Gil
出处
期刊:Allergy [Wiley]
卷期号:77 (1): 150-161 被引量:72
标识
DOI:10.1111/all.14902
摘要

Abstract Background Clinically meaningful improvement in the Sino‐Nasal Outcome Test‐22 (SNOT‐22) was observed in patients with severe, eosinophilic asthma, and nasal polyposis (NP) treated with benralizumab in the ANDHI trial. A post hoc assessment of the effects of benralizumab on SNOT‐22 response and asthma efficacy measures in these patients was conducted for further characterization of the efficacy and safety of benralizumab for patients with severe asthma and NP. Methods Adults with severe, eosinophilic asthma who had experienced ≥2 prior‐year exacerbations despite high‐dosage inhaled corticosteroid plus additional controller[s] were randomized to 24 weeks of benralizumab or placebo. Patients with physician‐diagnosed chronic rhinosinusitis with NP of any severity ongoing at baseline who consented to participate were included in the current ANDHI NP substudy population. Effect on NP symptoms was assessed by the SNOT‐22, with an improvement of at least 8.9 defined as clinically significant (responder). Effects on chronic asthma outcomes were assessed by means of annualized asthma exacerbation rate (AER), St. George's Respiratory Questionnaire (SGRQ) total score, forced expiratory volume in one second (FEV 1 ), and Asthma Control Questionnaire‐6 (ACQ‐6). All p ‐values were nominal. Results Of the ANDHI population ( n = 656), 23% ( n = 153) participated in the NP substudy ( n = 96 benralizumab; n = 57 placebo). Patients were 50% female, with mean age of 53 years, had prior‐year AER = 3.3; mean pre‐bronchodilator FEV 1 = 55% predicted; and median blood eosinophil count ​= 510 cells/µl. For patients with high baseline SNOT‐22 scores (>30), benralizumab treatment improved symptoms of NP as measured by SNOT‐22 from baseline to Week 24 compared with placebo (Week 24: −10.44 [ p = .0176]). Percentage of responders to SNOT‐22 was greater for benralizumab vs. placebo (71.3% vs. 45.5%; p = .0036), and effect was enhanced for patients with high baseline SNOT‐22 scores (>30). A 69% reduction vs. placebo in annualized AER (0.77 vs. 2.47; p < .0001) and greater clinically meaningful improvements from baseline in SGRQ total score (−16.7), FEV 1 (+0.32 L), and ACQ‐6 (–0.88) were observed ( p < .0001). Benralizumab was well‐tolerated. Frequency of adverse events (AEs) was similar for benralizumab (76.0%) and placebo (73.7%) groups. Most common AEs (frequency ≥5%) reported at a greater frequency in benralizumab vs. placebo included headache, sinusitis, pyrexia, and influenza. Conclusions These substudy data from ANDHI demonstrated the efficacy profile of benralizumab for patients with severe, eosinophilic asthma and NP, with improvement in SNOT‐22 and asthma outcomes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
闪闪的灵的应助被科研通管家采纳,获得10
刚刚
null的应助被科研通管家采纳,获得10
刚刚
打打的应助被科研通管家采纳,获得10
刚刚
心想事成完成签到,获得积分10
刚刚
领导范儿的应助被科研通管家采纳,获得10
刚刚
香蕉觅云的应助被科研通管家采纳,获得10
1秒前
Hello的应助被科研通管家采纳,获得10
1秒前
ZZZ发布了新的文献求助10
1秒前
完美世界的应助被科研通管家采纳,获得10
1秒前
极限001举报风格的求助涉嫌违规
1秒前
1秒前
JamesPei的应助被科研通管家采纳,获得10
1秒前
asa发布了新的文献求助10
1秒前
阿紫完成签到 ,获得积分10
1秒前
1秒前
1秒前
我是老大的应助被keyan采纳,获得10
1秒前
Owen的应助被科研通管家采纳,获得10
1秒前
机灵柚子的应助被科研通管家采纳,获得10
1秒前
null的应助被科研通管家采纳,获得10
1秒前
hhh完成签到,获得积分10
2秒前
MeiLing发布了新的文献求助10
2秒前
我想以后完成签到,获得积分10
3秒前
yeahCZY完成签到,获得积分10
3秒前
3秒前
lmh发布了新的文献求助10
3秒前
Ren的应助被科研通管家采纳,获得10
3秒前
yang发布了新的文献求助10
3秒前
田様的应助被柚子采纳,获得10
3秒前
3秒前
华仔的应助被科研通管家采纳,获得10
3秒前
学术雷锋的应助被科研通管家采纳,获得10
3秒前
帅气东蒽完成签到,获得积分10
3秒前
吕狗蛋完成签到,获得积分10
3秒前
CipherSage的应助被科研通管家采纳,获得10
4秒前
Ava的应助被lmg采纳,获得10
4秒前
闪闪的灵的应助被科研通管家采纳,获得200
4秒前
4秒前
4秒前
4秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159790
求助须知:如何正确求助?哪些是违规求助? 9555224
关于积分的说明 21726021
捐赠科研通 7749765
什么是DOI,文献DOI怎么找? 3427296
关于科研通互助平台的介绍 2552375
邀请新用户注册赠送积分活动 2471654